Literature DB >> 33505402

FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

Stephanie Trend1,2, Jonatan Leffler1, Ingrid Teige3, Björn Frendéus3, Allan G Kermode2,4, Martyn A French5, Prue H Hart1.   

Abstract

B cells are critical to the development of multiple sclerosis (MS), but the mechanisms by which they contribute to the disease are poorly defined. We hypothesised that the expression of CD32b (FcγRIIb), a receptor for the Fc region of IgG with inhibitory activities in B cells, is lower on B cell subsets from people with clinically isolated syndrome (CIS) or MS. CD32b expression was highest on post-naive IgM+ B cell subsets in healthy controls. For females with MS or CIS, significantly lower CD32b expression was identified on IgM+ B cell subsets, including naive and IgMhi MZ-like B cells, when compared with control females. Lower CD32b expression on these B cell subsets was associated with detectable anti-Epstein Barr Virus viral capsid antigen IgM antibodies, and higher serum levels of B cell activating factor. To investigate the effects of lower CD32b expression, B cells were polyclonally activated in the presence of IgG immune complexes, with or without a CD32b blocking antibody, and the expression of TNF and IL-10 in B cell subsets was assessed. The reduction of TNF but not IL-10 expression in controls mediated by IgG immune complexes was reversed by CD32b blockade in naive and IgMhi MZ-like B cells only. However, no consequence of lower CD32b expression on these cells from females with CIS or MS was detected. Our findings highlight a potential role for naive and marginal zone-like B cells in the immunopathogenesis of MS in females, which requires further investigation.
Copyright © 2021 Trend, Leffler, Teige, Frendéus, Kermode, French and Hart.

Entities:  

Keywords:  B cells; Epstein-Barr virus; FcγRIIb; females; immune regulation; multiple sclerosis

Year:  2021        PMID: 33505402      PMCID: PMC7832177          DOI: 10.3389/fimmu.2020.614492

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  79 in total

1.  B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.

Authors:  Min Yang; Hidenori Hase; Diana Legarda-Addison; Leena Varughese; Brian Seed; Adrian T Ting
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.

Authors:  Ali Roghanian; Ingrid Teige; Linda Mårtensson; Kerry L Cox; Mathilda Kovacek; Anne Ljungars; Jenny Mattson; Annika Sundberg; Andrew T Vaughan; Vallari Shah; Neil R Smyth; Bhavwanti Sheth; H T Claude Chan; Zhan-Chun Li; Emily L Williams; Giusi Manfredi; Robert J Oldham; C Ian Mockridge; Sonya A James; Lekh N Dahal; Khiyam Hussain; Björn Nilsson; J Sjef Verbeek; Gunnar Juliusson; Markus Hansson; Mats Jerkeman; Peter W M Johnson; Andrew Davies; Stephen A Beers; Martin J Glennie; Björn Frendéus; Mark S Cragg
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

3.  B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS.

Authors:  Manuel Comabella; Xavier Montalban; Kristina Kakalacheva; Deeqa Osman; Falk Nimmerjahn; Mar Tintoré; Jan D Lünemann
Journal:  J Neuroimmunol       Date:  2010-06       Impact factor: 3.478

4.  Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.

Authors:  R Egg; M Reindl; F Deisenhammer; C Linington; T Berger
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

5.  Restoration of tolerance in lupus by targeted inhibitory receptor expression.

Authors:  Tracy L McGaha; Brian Sorrentino; Jeffrey V Ravetch
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

6.  Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS.

Authors:  K M Myhr; G Raknes; H Nyland; C Vedeler
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

Review 7.  Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Authors:  David Baker; Monica Marta; Gareth Pryce; Gavin Giovannoni; Klaus Schmierer
Journal:  EBioMedicine       Date:  2017-01-31       Impact factor: 8.143

8.  Higher Serum Immunoglobulin G3 Levels May Predict the Development of Multiple Sclerosis in Individuals With Clinically Isolated Syndrome.

Authors:  Stephanie Trend; Anderson P Jones; Lilian Cha; Scott N Byrne; Sian Geldenhuys; Marzena J Fabis-Pedrini; William M Carroll; Judith M Cole; David R Booth; Robyn M Lucas; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2018-07-13       Impact factor: 7.561

9.  High Levels of Epstein-Barr Virus Nuclear Antigen-1-Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk.

Authors:  Anna Karin Hedström; Jesse Huang; Angelica Michel; Julia Butt; Nicole Brenner; Jan Hillert; Tim Waterboer; Ingrid Kockum; Tomas Olsson; Lars Alfredsson
Journal:  Front Neurol       Date:  2020-01-24       Impact factor: 4.003

10.  Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.

Authors:  Karin Kannel; Kristi Alnek; Liina Vahter; Katrin Gross-Paju; Raivo Uibo; Kalle V Kisand
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more
  2 in total

1.  Associations of serum short-chain fatty acids with circulating immune cells and serum biomarkers in patients with multiple sclerosis.

Authors:  Stephanie Trend; Jonatan Leffler; Anderson P Jones; Lilian Cha; Shelley Gorman; David A Brown; Samuel N Breit; Allan G Kermode; Martyn A French; Natalie C Ward; Prue H Hart
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

2.  Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM+ Cell Signature.

Authors:  Jonatan Leffler; Stephanie Trend; Natalie C Ward; Georges E Grau; Simon Hawke; Scott N Byrne; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.